Related Experiment Videos
Selective cyclooxygenase-2 inhibitors: similarities and differences.
1Department of Experimental and Clinical Pharmacology and Toxicology, Emil Fischer Center, Friedrich Alexander University, Erlangen, Germany. brune@pharmakologie.uni-erlangen.de
Scandinavian Journal of Rheumatology
|May 6, 2004
Summary
Selective cyclooxygenase-2 (COX-2) inhibitors offer anti-inflammatory benefits with fewer gastrointestinal risks than traditional NSAIDs. This review compares the pharmacokinetics of various COX-2 inhibitors, including celecoxib and rofecoxib.
Area of Science:
- Biochemistry
- Pharmacology
- Medicinal Chemistry
Background:
- Cyclooxygenase (COX) exists as two isoforms: COX-1 (housekeeping) and COX-2 (inflammation-related).
- COX-2 is primarily responsible for prostanoid synthesis in inflammatory conditions.
- Selective COX-2 inhibition was developed to achieve anti-inflammatory effects with reduced gastrointestinal side effects.
Purpose of the Study:
- To review and compare clinically relevant selective COX-2 inhibitors.
- To emphasize the diverse pharmacokinetic characteristics of these drugs.
Main Methods:
- Literature review of selective COX-2 inhibitors.
- Comparative analysis of pharmacokinetic profiles.
Main Results:
- Several selective COX-2 inhibitors are available, including sulphonamides (celecoxib, valdecoxib) and methylsulphones (rofecoxib, etoricoxib).
- A phenylacetic acid derivative, lumiracoxib, is also marketed.
- Significant pharmacokinetic differences exist among these agents.
Conclusions:
- Selective COX-2 inhibitors represent a therapeutic advance for inflammatory conditions.
- Understanding their pharmacokinetic differences is crucial for clinical application.